Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

NCT02496663 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

138

Enrollment

NIH

Sponsor class

Conditions

Metastatic Lung Non-Small Cell Carcinoma
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
PROCEDURE: Echocardiography Test
PROCEDURE: Magnetic Resonance Elastography
PROCEDURE: Multigated Acquisition Scan
BIOLOGICAL: Necitumumab
DRUG: Osimertinib

Sponsor

National Cancer Institute (NCI)